Mastopon-Treat New

Progesterone, the active ingredient in Mastopon-Treat New, is a progestogen presented as a vaginal formulation for vaginal use. It is used to support the luteal phase, aid endometrial development and help prevent preterm birth in appropriate patients.

GNH USA supplies Mastopon-Treat New as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Progesterone acts on the reproductive hormonal pathway and is employed in several obstetric and gynecologic contexts.

- Luteal phase support: enhances endometrial receptivity during assisted reproductive technology cycles. - Prevention of preterm birth: reduces the risk of early delivery in women with a short cervix or a history of preterm labor. - Endometrial preparation: facilitates adequate endometrial thickness for embryo implantation or hormone replacement protocols.

Progesterone administered vaginally may be associated with a range of adverse reactions.

Common Side Effects: - Vaginal irritation or itching: mild discomfort at the application site. - Increased vaginal discharge: watery or milky secretion. - Abdominal cramps or pelvic discomfort. - Breast tenderness or swelling. - Headache: mild to moderate intensity. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Allergic reaction: rash, hives, or swelling of face and throat. - Severe abdominal pain: may indicate underlying complications. - Pulmonary embolism: rare but potentially life‑threatening clotting event. - Hyperglycemia: elevated blood glucose in susceptible individuals. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

When prescribing or dispensing vaginal progesterone, consider the following safety measures.

- Contraindications: avoid use in patients with known hypersensitivity to progesterone or its excipients. - Thromboembolic risk: use with caution in individuals with a history of clotting disorders. - Hormone‑sensitive cancers: assess risk before initiating therapy in patients with breast or endometrial cancer. - Liver function: monitor hepatic parameters in patients with pre‑existing liver disease. - Pregnancy monitoring: ensure appropriate obstetric follow‑up during use. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Progesterone may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase progesterone levels. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce progesterone efficacy. - Hormonal contraceptives: potential additive hormonal effects. - Antiepileptic drugs: may alter hormone metabolism. - Antifungal azoles (e.g., fluconazole): possible modest increase in progesterone exposure.